Davis Polk & Wardwell LLP-led Novo Nordisk will acquire Goodwin Procter LLP-advised Forma Therapeutics Holdings Inc., which develops treatments for sickle cell disease and rare blood disorders, for a total equity value of $1.1 billion, the companies announced Thursday.